108 related articles for article (PubMed ID: 36209968)
21. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
23. Design and evaluation of ionizable peptide amphiphiles for siRNA delivery.
Neuberg P; Wagner A; Remy JS; Kichler A
Int J Pharm; 2019 Jul; 566():141-148. PubMed ID: 31125716
[TBL] [Abstract][Full Text] [Related]
24. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
[TBL] [Abstract][Full Text] [Related]
25. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.
Jeter CR; Liu B; Liu X; Chen X; Liu C; Calhoun-Davis T; Repass J; Zaehres H; Shen JJ; Tang DG
Oncogene; 2011 Sep; 30(36):3833-45. PubMed ID: 21499299
[TBL] [Abstract][Full Text] [Related]
26. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells.
Cantini L; Attaway CC; Butler B; Andino LM; Sokolosky ML; Jakymiw A
PLoS One; 2013; 8(9):e73348. PubMed ID: 24019920
[TBL] [Abstract][Full Text] [Related]
27. Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline.
Felipe AV; Oliveira J; Moraes AA; França JP; Silva TD; Forones NM
Asian Pac J Cancer Prev; 2018 May; 19(5):1237-1242. PubMed ID: 29801407
[TBL] [Abstract][Full Text] [Related]
28. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
29. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
30. Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
Alexander-Bryant AA; Zhang H; Attaway CC; Pugh W; Eggart L; Sansevere RM; Andino LM; Dinh L; Cantini LP; Jakymiw A
Oral Oncol; 2017 Sep; 72():123-131. PubMed ID: 28797448
[TBL] [Abstract][Full Text] [Related]
31. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
32. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
33. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.
Paduano F; Villa R; Pennati M; Folini M; Binda M; Daidone MG; Zaffaroni N
Mol Cancer Ther; 2006 Jan; 5(1):179-86. PubMed ID: 16432177
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
35. Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells.
He C; Lu K; Liu D; Lin W
J Am Chem Soc; 2014 Apr; 136(14):5181-4. PubMed ID: 24669930
[TBL] [Abstract][Full Text] [Related]
36. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression.
Zhou JJ; Deng XG; He XY; Zhou Y; Yu M; Gao WC; Zeng B; Zhou QB; Li ZH; Chen RF
Int J Oncol; 2014 Jun; 44(6):2034-40. PubMed ID: 24647772
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells.
Kawamura N; Nimura K; Nagano H; Yamaguchi S; Nonomura N; Kaneda Y
Oncotarget; 2015 Sep; 6(26):22361-74. PubMed ID: 26087476
[TBL] [Abstract][Full Text] [Related]
39. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
Lo YL; Wang W
Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
[TBL] [Abstract][Full Text] [Related]
40. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
